Menu Search
Equities

Eris Lifesciences Ltd

ERIS:NSI

Eris Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,468.10
  • Today's Change-16.90 / -1.14%
  • Shares traded151.72k
  • 1 Year change+58.89%
  • Beta0.7401
Data delayed at least 15 minutes, as of Nov 26 2024 08:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in INR

The 8 analysts offering 12 month price targets for Eris Lifesciences Ltd have a median target of 1,505.00, with a high estimate of 1,680.00 and a low estimate of 1,230.00. The median estimate represents a 1.35% increase from the last price of 1,485.00.
High13.1%1,680.00
Med1.3%1,505.00
Low-17.2%1,230.00

Dividends

Historical dividend information is not available for Eris Lifesciences Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in INR

On Oct 25, 2024, Eris Lifesciences Ltd reported 2nd quarter 2025 earnings of 6.72 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 2nd quarter results by 25.83%.
The next earnings announcement is expected on May 19, 2025.
Average growth rate-5.11%
Eris Lifesciences Ltd reported annual 2024 earnings of 28.79 per share on May 21, 2024.
Average growth rate+7.99%
More ▼

Revenue history & estimates in INR

Eris Lifesciences Limited had 2nd quarter 2025 revenues of 7.41bn. This bettered the 7.29bn consensus of the 5 analysts covering the company. This was 58.84% above the prior year's 2nd quarter results.
Average growth rate+10.79%
Eris Lifesciences Limited had revenues for the full year 2024 of 20.09bn. This was 19.23% above the prior year's results.
Average growth rate+17.08%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.